Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s near-term focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition. 

LATEST NEWS
UPCOMING PRESENTATION
Presentation Year-end report 2023
February 23 2024
11:00 CET
For more information and webcast
SEVUPARIN AND SEPSIS IN LESS THAN THREE MINUTES